The Benefits of Adjuvant Trastuzumab for HER‐2‐Positive Salivary Gland Cancers

BACKGROUND: Although high‐grade salivary gland cancers (SGCs) often express androgen receptor (AR) and/or HER‐2/neu, therapeutically targeting these receptors in SGC remains investigational. We investigated the prevalence of receptor expression and the benefit of adjuvant HER‐2 directed therapy in t...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncologist
Hoofdauteurs: Hanna, Glenn J., Bae, Ji Eun, Lorch, Jochen H., Haddad, Robert I., Jo, Vickie Y., Schoenfeld, Jonathan D., Margalit, Danielle N., Tishler, Roy B., Goguen, Laura A., Annino, Donald J., Chau, Nicole G.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley & Sons, Inc. 2020
Onderwerpen:
Head and Neck Cancers
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356716/
https://ncbi.nlm.nih.gov/pubmed/32310325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0841
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items